Vis enkel innførsel

dc.contributor.authorJørgensen, Silje Fjellgården_US
dc.contributor.authorMacpherson, Magnhild Eideen_US
dc.contributor.authorBjørnetrø, Tonjeen_US
dc.contributor.authorHolm, Kristianen_US
dc.contributor.authorKummen, Martinen_US
dc.contributor.authorRashidi, Azitaen_US
dc.contributor.authorMichelsen, Annikaen_US
dc.contributor.authorLekva, Toveen_US
dc.contributor.authorHalvorsen, Benteen_US
dc.contributor.authorTrøseid, Mariusen_US
dc.contributor.authorMollnes, Tom Eiriken_US
dc.contributor.authorBerge, Rolf Kristianen_US
dc.contributor.authorYndestad, Arneen_US
dc.contributor.authorUeland, Thoren_US
dc.contributor.authorKarlsen, Tom Hemmingen_US
dc.contributor.authorAukrust, Pålen_US
dc.contributor.authorHov, Johannes Espolin Roksunden_US
dc.contributor.authorFevang, Børreen_US
dc.PublishedJørgensen S, Macpherson M, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen A, Lekva T, Halvorsen BE, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen HT, Aukrust P, Hov JR, Fevang B. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Scientific Reports. 2019;9:167.eng
dc.description.abstractCommon variable immunodefciency (CVID) patients have reduced gut microbial diversity compared to healthy controls. The reduced diversity is associated with gut leakage, increased systemic infammation and ten “key” bacteria that capture the gut dysbiosis (dysbiosis index) in CVID. Rifaximin is a broadspectrum non-absorbable antibiotic known to reduce gut leakage (lipopolysaccharides, LPS) in liver disease. In this study, we explored as a ‘proof of concept’ that altering gut microbial composition could reduce systemic infammation, using CVID as a disease model. Forty adult CVID patients were randomized, (1:1) to twice-daily oral rifaximin 550mg versus no treatment for 2 weeks in an openlabel, single-centre study. Primary endpoints were reduction in plasma/serum levels of soluble (s) CD14, sCD25, sCD163, neopterin, CRP, TNF, LPS and selected cytokines measured at 0, 2 and 8 weeks. Secondary endpoint was changes in intra-individual bacterial diversity in stool samples. Rifaximinuse did not signifcantly change any of the infammation or gut leakage markers, but decreased gut microbial diversity compared with no treatment (p=0.002). Importantly, the gut bacteria in the CVID dysbiosis index were not changed by rifaximin. The results suggest that modulating gut microbiota by rifaximin is not the chosen intervention to afect systemic infammation, at least not in CVID.en_US
dc.publisherNature Researcheng
dc.rightsAttribution CC BYeng
dc.titleRifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiencyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Author(s).
dc.source.journalScientific Reports

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY